Skip to main content
SpringerLink
Log in

Schizophrenia — patients and costs increasingly being shifted from institutions to the community

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cohen CI. Poverty and the course of schizophrenia: implications for research and policy. Hosp Community Psychiatry 1993 Oct; 44(10): 951–58

    PubMed  CAS  Google Scholar 

  2. Terkelson KG, Menikoff A. Measuring the costs of schizophrenia. PharmacoEconomics 1995 Sep; 8(3): 199–222

    Article  Google Scholar 

  3. Frankenburg FR, Hegarty JD. Cost considerations in the treatment of schizophrenia. CNS Drugs 1996 Jan; 5(1): 75–82

    Article  Google Scholar 

  4. Jolley AG, Hirsch SR. Continuous versus intermittent neuroleptic therapy in schizophrenia. Drug Saf 1993 May; 8(5): 331–9

    Article  PubMed  CAS  Google Scholar 

  5. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994 Mar 10; 330(10): 681–90

    Article  PubMed  Google Scholar 

  6. Bosanquet N. Schizophrenia: developing new strategies for effective care. Br J Med Econ 1995; 8: 51–64

    Google Scholar 

  7. Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment: II. Economic benefit-cost analysis. Arch Gen Psychiatry 1980; 37(4): 400–5

    Article  PubMed  CAS  Google Scholar 

  8. Hornstra RK, Bruce-Wolfe V, Sagduyu K, et al. The effect of intensive case management on hospitalization of patients with schizophrenia. Hosp Community Psychiatry 1993; 44(9): 844–7

    PubMed  CAS  Google Scholar 

  9. Dixon L, Friedman N, Lehman A. Compliance of homeless mentally ill persons with assertive community treatment. Hosp Community Psychiatry 1993; 44(6): 581–3

    PubMed  CAS  Google Scholar 

  10. Santos AB, Deci PA, Lachance KR, et al. Providing assertive community treatment of severely mentally ill patients in a rural area. Hosp Community Psychiatry 1993; 44(1): 34–9

    PubMed  CAS  Google Scholar 

  11. Dincin J, Wasmer D, Witheridge TF, et al. Impact of assertive community treatment of the use of state hospital inpatient bed-days. Hosp Community Psychiatry 1993; 44(9): 833–8

    PubMed  CAS  Google Scholar 

  12. Olfson M. Assertive community treatment: an evaluation of the experimental evidence. Hosp Community Psychiatry 1990; 41: 634–41

    PubMed  CAS  Google Scholar 

  13. Clozapine: indications are defined by clinical not economic criteria. Drug Ther Perspect 1993 Nov 22; 2(10): 5–7

    Google Scholar 

  14. Soumerai SB, McLaughlin TJ, Ross-Denegan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994 Sep 8; 331: 650–5

    Article  PubMed  CAS  Google Scholar 

  15. Goldberg D. Cost-effectiveness in the treatment of patients with schizophrenia. Acta Psychiatr Scand 1994; 89 Suppl. 382: 89–92

    Article  Google Scholar 

  16. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatr 1993 Nov; 150(11): 1630–8

    PubMed  CAS  Google Scholar 

  17. Jones R, Goldberg D, Hughes B. A comparison of two different services treating schizophrenia: a cost-benefit approach. Psychol Med 1980; 10: 493–305

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schizophrenia — patients and costs increasingly being shifted from institutions to the community. Drugs Ther. Perspect 7, 13–16 (1996). https://doi.org/10.2165/00042310-199607060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607060-00007

Keywords

Search

Navigation